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2008-2009 Influenza Season 
Week 22 ending June 6, 2009 
All data are preliminary and may change as more reports are received. 
Synopsis:  During week 22 (May 31 – June 6, 2009), influenza activity decreased in the United 
States, however, there are still higher levels of influenza-like illness than is normal for this time of 
year.   
o Two thousand six hundred eighty-one (40.2%) specimens tested by U.S. World Health 
Organization (WHO) and National Respiratory and Enteric Virus Surveillance System 
(NREVSS) collaborating laboratories and reported to CDC/Influenza Division were positive 
for influenza. 
o Approximately 89% of all influenza viruses being reported to CDC were novel influenza A 
(H1N1) viruses. 
o The proportion of deaths attributed to pneumonia and influenza (P&I) was below the 
epidemic threshold.  
o Three influenza-associated pediatric deaths were reported; two were associated with novel 
influenza A (H1N1) virus infection and one was associated with seasonal influenza A 
(H1N1) virus infection. 
o The proportion of outpatient visits for influenza-like illness (ILI) was below the national 
baseline.  Two of the 10 surveillance regions reported ILI above their region-specific 
baseline. 
o Eight states reported geographically widespread influenza activity, nine states reported 
regional influenza activity, the District of Columbia, Puerto Rico, and 15 states reported local 
influenza activity, 17 states reported sporadic influenza activity, and one state did not report. 
 
National and Regional Summary of Select Surveillance Components 
 Data for current week Data cumulative for the season 
HHS 
Surveillance 
Regions* 
Out-
patient 
ILI† 
% 
positive 
for flu‡ 
Number of  
jurisdictions 
reporting 
regional or 
widespread 
activity§  
A (H1) A (H3) Novel A H1N1
A  
(could 
not be 
sub-
typed)¥ 
A 
 (Un-
sub-
typed) 
B  Pediatric Deaths 
Nation Normal 40.2% 17 of 52 7,650 2,088 9,139 952 12,829 10,303 70 
Region I Elevated 34.5% 4 of 6 520 151 1,232 13 1,173 800 1 
Region II Elevated 31.1% 2 of 3 277 135 467 16 1,339 710 9 
Region III Normal 50.8% 3 of 6 1,237 204 815 558 644 1,359 9 
Region IV Normal 13.0% 2 of 8 828 117 211 37 1,791 1,202 6 
Region V Normal 44.6% 1 of 6 1,653 183 4,322 123 526 1,305 11 
Region VI Normal 14.5% 1 of 5 748 145 701 5 4,058 2,583 14 
Region VII Normal 10.9% 0 of 4 497 59 145 98 446 529 0 
Region VIII Normal 23.9% 1 of 6 471 211 679 57 1,489 493 6 
Region IX Normal 10.4% 3 of 4 1,045 600 390 13 1,027 658 13 
Region X Normal 20.9% 0 of 4 374 283 177 32 336 664 1 
* HHS regions (Region I: CT, ME, MA, NH, RI, VT; Region II: NJ, NY, Puerto Rico, US Virgin Islands; Region III: DE, DC, MD, PA, VA, WV; Region IV: AL, 
FL, GA, KY, MS, NC, SC, TN; Region V: IL, IN, MI, MN, OH, WI; Region VI: AR, LA, NM, OK, TX; Region VII: IA, KS, MO, NE; Region VIII: CO, MT, ND, 
SD, UT, WY; Region IX: AZ, CA, Guam, HI, NV; and Region X: AK, ID, OR, WA) 
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline 
‡ National data are for current week; regional data are for the most recent three weeks 
§ Includes all 50 states, the District of Columbia, and Puerto Rico 
¥ The majority of influenza A viruses that cannot be sub-typed as seasonal influenza viruses are novel A (H1N1) influenza viruses upon further testing 
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U.S. Virologic Surveillance:  WHO and NREVSS collaborating laboratories located in all 50 states 
and Washington D.C. report to CDC the number of respiratory specimens tested for influenza.  
 
During the 2008-09 season, influenza A (H1), A (H3), and B viruses have co-circulated in the United 
States.  On April 15 and 17, 2009, CDC confirmed the first two cases novel influenza A (H1N1) 
virus in the United States. As of June 12, 2009, 17,855 confirmed and probable infections with 
novel influenza A (H1N1) virus have been identified by CDC and state and local public health 
departments.  Reporting of novel influenza A (H1N1) viruses by U.S. WHO collaborating 
laboratories began during week 17 (week ending May 2, 2009).  The results of tests performed 
during the current week are summarized in the table below. 
 
 Week 22 
No. of specimens tested 6,664 
No. of positive specimens (%) 2,681 (40.2%) 
Positive specimens by type/subtype  
Influenza A              2,663 (99.3%) 
        A (H1)              9 (0.3%) 
        A (H3)            22 (0.8%) 
        A (unsubtyped)           246 (9.2%) 
        A (could not be subtyped)                      315 (11.8%) 
        A (novel influenza H1N1)                   2,071 (77.8%) 
Influenza B                  18 (0.7%) 
 
During week 22, seasonal influenza A (H1), A (H3), and B viruses co-circulated at low levels with 
novel influenza A (H1N1).  Approximately 89% of all influenza viruses being reported to CDC this 
week are novel influenza A (H1N1) viruses. 
 
The increase in the percentage of specimens testing positive for influenza by WHO and NREVSS 
collaborating laboratories may be due in part to changes in testing practices by health care 
providers, triaging of specimens by public health laboratories, an increase in the number of 
specimens collected from outbreaks, and other factors. 
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Influenza Positive Tests Reported to CDC by U.S. WHO/NREVSS 
Collaborating Laboratories, National Summary, 2008-09 
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Antigenic Characterization:  CDC has antigenically characterized 1,626 seasonal human 
influenza viruses [947 influenza A (H1), 162 influenza A (H3) and 517 influenza B viruses] collected 
by U.S. laboratories since October 1, 2008, and 125 novel influenza A (H1N1) viruses. 
All 947 influenza seasonal A (H1) viruses are related to the influenza A (H1N1) component of the 
2008-09 influenza vaccine (A/Brisbane/59/2007).  All 162 influenza A (H3N2) viruses are related 
to the A (H3N2) vaccine component (A/Brisbane/10/2007).  
All 125 novel influenza A (H1N1) viruses are related to the A/California/07/2009 (H1N1) reference 
virus selected by WHO as a potential candidate for novel influenza A (H1N1) vaccine. 
Influenza B viruses currently circulating can be divided into two distinct lineages represented by the 
B/Yamagata/16/88 and B/Victoria/02/87 viruses. Sixty-five influenza B viruses tested belong to the 
B/Yamagata lineage and are related to the vaccine strain (B/Florida/04/2006). The remaining 452 
viruses belong to the B/Victoria lineage and are not related to the vaccine strain.  
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Data on antigenic characterization should be interpreted with caution given that antigenic 
characterization data is based on hemagglutination inhibition (HI) testing using a panel of reference 
ferret antisera and results may not correlate with clinical protection against circulating viruses 
provided by influenza vaccination. 
Annual influenza vaccination is expected to provide the best protection against those virus 
strains that are related to the vaccine strains, but limited to no protection may be expected when the 
vaccine and circulating virus strains are so different as to be from different lineages, as is seen with 
the two lineages of influenza B viruses.  Antigenic characterization of novel influenza A (H1N1) 
viruses indicates that these viruses are antigenically and genetically unrelated to seasonal influenza 
A (H1N1) viruses, suggesting that little to no protection would be expected from vaccination with 
seasonal influenza vaccine.  
Antiviral Resistance: Since October 1, 2008, 975 seasonal influenza A (H1N1), 169 influenza A 
(H3N2), and 508 influenza B viruses have been tested for resistance to the neuraminidase 
inhibitors (oseltamivir and zanamivir).  Nine hundred eighty-one seasonal influenza A (H1N1) and 
172 influenza A (H3N2) viruses have been tested for resistance to the adamantanes (amantadine 
and rimantadine).  One hundred eighty-four novel influenza A (H1N1) viruses have been tested for 
resistance to the neuraminidase inhibitors (oseltamivir and zanamivir).  One hundred forty-one 
novel influenza A (H1N1) viruses have been tested for resistance to the adamantanes (amantadine 
and rimantadine).  The results of antiviral resistance testing performed on these viruses are 
summarized in the table below. 
 
Resistant Viruses, 
Number (%) 
Resistant 
Viruses, Number 
(%)  Isolates tested (n) 
Oseltamivir Zanamivir 
Isolates 
tested (n) 
Adamantanes 
Seasonal Influenza 
A (H1N1) 975 970 (99.5%) 0 (0) 981 5 (0.5%) 
Influenza A (H3N2) 169 0 (0) 0 (0) 172 172 (100%) 
Influenza B 508 0 (0) 0 (0) N/A* N/A* 
Novel Influenza A  
(H1N1) 184 0 (0) 0 (0) 141 141 (100%) 
*The adamantanes (amantadine and rimantadine) are not effective against influenza B viruses. 
 
Antiviral treatment with either oseltamivir or zanamivir is recommended for all patients with 
confirmed, probable or suspected cases of novel influenza A (H1N1) virus infection who are 
hospitalized or who are at higher risk for seasonal influenza complications.  The novel influenza A 
(H1N1) virus is susceptible to both neuraminidase inhibitor antiviral medications zanamivir and 
oseltamivir.  It is resistant to the adamantane antiviral medications, amantadine and 
rimantadine. Additional information on antiviral recommendations for treatment and 
chemoprophylaxis of novel influenza A (H1N1) infection is available at 
http://www.cdc.gov/h1n1flu/recommendations.htm 
 
In areas that continue to have seasonal influenza activity, especially those with circulation of 
oseltamivir-resistant seasonal human influenza A (H1N1) viruses, clinicians might prefer to use 
either zanamivir or a combination of oseltamivir and either rimantadine or amantadine to provide 
adequate empiric treatment or chemoprophylaxis for patients who might have seasonal human 
influenza A (H1N1) virus infection. 
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Pneumonia and Influenza (P&I) Mortality Surveillance:  During week 22, 6.4% of all deaths 
reported through the 122-Cities Mortality Reporting System were due to P&I. This percentage is 
below the epidemic threshold of 7.0% for week 22. 
 
 
Pneumonia and Influenza Mortality for 122 U.S. Cities 
Week ending 6/6/2009 
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Influenza-Associated Pediatric Mortality:  Three influenza-associated pediatric deaths were 
reported to CDC during week 22 (New York City, Oklahoma, and Texas).  Two of these deaths 
were associated with infections with novel influenza A (H1N1) viruses and one was due to seasonal 
influenza A (H1N1).  The deaths reported this week occurred between February 15, 2009 and May 
30, 2009.  Since September 28, 2008, CDC has received 70 reports of influenza-associated 
pediatric deaths that occurred during the current influenza season, five of which were due to 
confirmed novel influenza A (H1N1) virus infections.   
 
Of the 34 children who had specimens collected for bacterial culture from normally sterile sites, 14 
(41.2%) were positive; Staphylococcus aureus was identified in nine (64.3%) of the 14 children.  
One of the three children with confirmed novel influenza A (H1N1) infection had a specimen 
collected from a normally sterile site; bacterial cultures were negative.  Four of the S. aureus 
isolates were sensitive to methicillin and five were methicillin resistant.   Twelve (85.7%) of the 14 
children with bacterial coinfections were five years of age or older and 10 (71.4%) of the 14 children 
were 12 years of age or older.  An increase in the number of influenza-associated pediatric deaths 
with bacterial coinfections was first recognized during the 2006-07 influenza season.  In January 
2008, interim testing and reporting recommendations were released regarding influenza and 
bacterial coinfections in children and are available at 
(http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00268). 
 
 
Number of Influenza-Associated Pediatric Deaths by Week of Death: 
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Influenza-Associated Hospitalizations:  Laboratory-confirmed influenza-associated 
hospitalizations are monitored in two population-based surveillance networks: the New Vaccine 
Surveillance Network (NVSN) and the Emerging Infections Program (EIP).   
 
During October 12, 2008 to May 30, 2009, the preliminary laboratory-confirmed influenza-
associated hospitalization rate for children 0-4 years old in the NVSN was 3.85 per 10,000. 
Because of case identification methods utilized in this study, there is a delay from the date of 
hospitalization to the date of report.  
 
 
NVSN Influenza Laboratory-Confirmed Cumulative Hospitalization 
Rates for Children 0 - 4 Years, 2008-09 and Previous Three Seasons 
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During April 15, 2009 – June 6, 2009, the following preliminary laboratory-confirmed overall 
influenza associated hospitalization rates were reported by the EIP (rates include type A, type B, 
and confirmed Novel H1N1): 
 
Rates for children aged 0-23 months, 2-4 years, 5-9 years, and 10-17 years were 0.8, 0.1, 0.2, and 
0.08 per 10,000, respectively.  Rates for adults aged 18-29 years, 30-49 years, and ≥ 50 years, the 
overall flu rates were 0.06, 0.06, and 0.1 per 10,000, respectively. 
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EIP Influenza Laboratory-Confirmed Cumulative Hospitalization Rates, 
Spring/Summer 2009 
Week
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*This value represents an age group-specific average influenza rate from October 1 to 
April 30 from the 2005-06, 2006-07, and 2007-08 influenza seasons.
**Note: The scale for the 0-23 month age group differs from other age groups.  
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Outpatient Illness Surveillance: Nationwide during week 22, 1.9% of patient visits reported 
through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to 
influenza-like illness (ILI).  This percentage is below the national baseline of 2.4%. 
 
Percentage of Visits for Influenza-like Illness (ILI) Reported by  
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
National Summary, 2008-09 and Previous Two Seasons 
*There was no week 53 during the 2006-07 and 2007-08 seasons, therefore the week 53 data point for those seasons is an average of weeks 52 and 1.
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On a regional level, the percentage of outpatient visits for ILI ranged from 0.7% to 5.2%. Two of the 
10 surveillance regions reported an ILI percentage above their region specific baseline (Regions I 
and II).  ILI decreased during week 22 in eight of 10 regions compared to week 21.   
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists:  The 
influenza activity reported by state and territorial epidemiologists indicates geographic spread of 
both seasonal influenza and novel influenza A (H1N1) viruses and does not measure the severity of 
influenza activity. 
 
During week 22, the following influenza activity was reported: 
? Widespread influenza activity was reported by eight states (Arizona, Connecticut, Delaware, 
Massachusetts, New Jersey, New York, Pennsylvania, and Rhode Island). 
? Regional influenza activity was reported by nine states (Alabama, California, Hawaii, Illinois, 
Maine, South Carolina, Texas, Utah, and Virginia). 
? Local influenza activity was reported by the District of Columbia, Puerto Rico, and 15 states 
(Georgia, Kansas, Maryland, Michigan, Minnesota, Nevada, New Hampshire, New Mexico, 
North Carolina, Oklahoma, Tennessee, Vermont, Washington, Wisconsin, and Wyoming). 
? Sporadic activity was reported by 17 states (Alaska, Arkansas, Florida, Idaho, Indiana, Iowa, 
Kentucky, Louisiana, Mississippi, Missouri, Montana, Nebraska, North Dakota, Ohio, 
Oregon, South Dakota, and West Virginia). 
? One state did not report (Colorado). 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm 
 
Report prepared: June 12, 2009. 
 
